{"id":"https://openalex.org/W2901917768","doi":"https://doi.org/10.1080/14789450.2018.1543595","title":"The power of proteasome inhibition in multiple myeloma","display_name":"The power of proteasome inhibition in multiple myeloma","publication_year":2018,"publication_date":"2018-11-14","ids":{"openalex":"https://openalex.org/W2901917768","doi":"https://doi.org/10.1080/14789450.2018.1543595","mag":"2901917768","pmid":"https://pubmed.ncbi.nlm.nih.gov/30427223"},"language":"en","primary_location":{"id":"doi:10.1080/14789450.2018.1543595","doi":"https://doi.org/10.1080/14789450.2018.1543595","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14789450.2018.1543595","pdf_url":null,"source":{"id":"https://openalex.org/S96346590","display_name":"Expert Review of Proteomics","issn_l":"1478-9450","issn":["1478-9450","1744-8387"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Proteomics","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061196957","display_name":"Thomas A. Guerrero-Garcia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas A. Guerrero-Garcia","raw_affiliation_strings":["Division of Hematology and Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068511166","display_name":"Sara Gandolfi","orcid":"https://orcid.org/0000-0001-6207-4433","observed_orcids":["https://orcid.org/0000-0001-6207-4433"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara Gandolfi","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049711954","display_name":"Jacob P. Laubach","orcid":"https://orcid.org/0000-0001-7565-2052","observed_orcids":["https://orcid.org/0000-0001-7565-2052"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacob P. Laubach","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091207345","display_name":"Teru Hideshima","orcid":"https://orcid.org/0000-0003-2939-6224","observed_orcids":["https://orcid.org/0000-0003-2939-6224"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Teru Hideshima","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006765393","display_name":"Dharminder Chauhan","orcid":"https://orcid.org/0000-0002-5548-6138","observed_orcids":["https://orcid.org/0000-0002-5548-6138"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dharminder Chauhan","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012712111","display_name":"Constantine S. Mitsiades","orcid":"https://orcid.org/0000-0003-2321-8005","observed_orcids":["https://orcid.org/0000-0003-2321-8005"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Constantine Mitsiades","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth C. Anderson","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043526996","display_name":"Paul Gerard Guy Richardson","orcid":"https://orcid.org/0000-0002-7426-8865","observed_orcids":["https://orcid.org/0000-0002-7426-8865"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Paul G. Richardson","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5043526996"],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":null,"apc_paid":null,"fwci":1.0454,"has_fulltext":false,"cited_by_count":38,"citation_normalized_percentile":{"value":0.71525753,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"15","issue":"12","first_page":"1033","last_page":"1052"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.9729999899864197},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":1.0},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":1.0},{"id":"https://openalex.org/keywords/carfilzomib","display_name":"carfilzomib","score":1.0},{"id":"https://openalex.org/keywords/ixazomib","display_name":"ixazomib","score":1.0},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6370000243186951},{"id":"https://openalex.org/keywords/relapsed-multiple-myeloma","display_name":"relapsed multiple myeloma","score":0.7739999890327454},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7789999842643738},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.5370000004768372},{"id":"https://openalex.org/keywords/signaling-pathways","display_name":"signaling pathways","score":0.5220000147819519}],"concepts":[{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.8923043012619019},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.8345106840133667},{"id":"https://openalex.org/C2781098529","wikidata":"https://www.wikidata.org/wiki/Q20948663","display_name":"Ixazomib","level":5,"score":0.8085256218910217},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.7453708648681641},{"id":"https://openalex.org/C27740335","wikidata":"https://www.wikidata.org/wiki/Q14878333","display_name":"Proteasome","level":2,"score":0.621414840221405},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5854254364967346},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.5057930946350098},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.45820167660713196},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.3674349784851074},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3481329083442688},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.18639639019966125},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1681150496006012},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061988","descriptor_name":"Proteasome Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D061988","descriptor_name":"Proteasome Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1080/14789450.2018.1543595","doi":"https://doi.org/10.1080/14789450.2018.1543595","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14789450.2018.1543595","pdf_url":null,"source":{"id":"https://openalex.org/S96346590","display_name":"Expert Review of Proteomics","issn_l":"1478-9450","issn":["1478-9450","1744-8387"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Proteomics","raw_type":"journal-article"},{"id":"pmid:30427223","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30427223","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert review of proteomics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.979200005531311,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320310151","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":150,"referenced_works":["https://openalex.org/W1516702206","https://openalex.org/W1544981048","https://openalex.org/W1759028523","https://openalex.org/W1773271542","https://openalex.org/W1804942062","https://openalex.org/W1898969431","https://openalex.org/W1938721925","https://openalex.org/W1952760452","https://openalex.org/W1955748620","https://openalex.org/W1963853457","https://openalex.org/W1967438746","https://openalex.org/W1978735501","https://openalex.org/W1979068418","https://openalex.org/W1980168719","https://openalex.org/W1981758758","https://openalex.org/W1985275612","https://openalex.org/W1985864219","https://openalex.org/W1987583882","https://openalex.org/W1989740966","https://openalex.org/W1993959807","https://openalex.org/W1999177459","https://openalex.org/W1999964913","https://openalex.org/W2006798542","https://openalex.org/W2012832145","https://openalex.org/W2013370486","https://openalex.org/W2015003025","https://openalex.org/W2015668100","https://openalex.org/W2020298011","https://openalex.org/W2023661149","https://openalex.org/W2025579499","https://openalex.org/W2033944464","https://openalex.org/W2037132614","https://openalex.org/W2039496823","https://openalex.org/W2050829096","https://openalex.org/W2055338149","https://openalex.org/W2067653691","https://openalex.org/W2068889400","https://openalex.org/W2070790769","https://openalex.org/W2073817882","https://openalex.org/W2079278201","https://openalex.org/W2082863510","https://openalex.org/W2083365324","https://openalex.org/W2088674645","https://openalex.org/W2088765731","https://openalex.org/W2089311432","https://openalex.org/W2090310344","https://openalex.org/W2091378741","https://openalex.org/W2095384810","https://openalex.org/W2096207943","https://openalex.org/W2096367061","https://openalex.org/W2102088366","https://openalex.org/W2104039873","https://openalex.org/W2106692847","https://openalex.org/W2109371953","https://openalex.org/W2111650326","https://openalex.org/W2117237065","https://openalex.org/W2120590293","https://openalex.org/W2120780398","https://openalex.org/W2124560610","https://openalex.org/W2124668830","https://openalex.org/W2126267349","https://openalex.org/W2129937834","https://openalex.org/W2131491521","https://openalex.org/W2131574772","https://openalex.org/W2133268402","https://openalex.org/W2134401047","https://openalex.org/W2134902298","https://openalex.org/W2135788003","https://openalex.org/W2138102966","https://openalex.org/W2141105112","https://openalex.org/W2142368474","https://openalex.org/W2143538182","https://openalex.org/W2144118007","https://openalex.org/W2144797350","https://openalex.org/W2145412346","https://openalex.org/W2150878522","https://openalex.org/W2152065071","https://openalex.org/W2153716391","https://openalex.org/W2158106888","https://openalex.org/W2159195400","https://openalex.org/W2160088903","https://openalex.org/W2162771614","https://openalex.org/W2165065963","https://openalex.org/W2168980644","https://openalex.org/W2169183166","https://openalex.org/W2169295136","https://openalex.org/W2169590701","https://openalex.org/W2193716145","https://openalex.org/W2198387358","https://openalex.org/W2215693941","https://openalex.org/W2234403337","https://openalex.org/W2316542938","https://openalex.org/W2319764074","https://openalex.org/W2343016172","https://openalex.org/W2343386476","https://openalex.org/W2343425851","https://openalex.org/W2403983357","https://openalex.org/W2408823699","https://openalex.org/W2419422146","https://openalex.org/W2424457748","https://openalex.org/W2460673902","https://openalex.org/W2489715554","https://openalex.org/W2494644907","https://openalex.org/W2512106959","https://openalex.org/W2512928744","https://openalex.org/W2513938433","https://openalex.org/W2517106444","https://openalex.org/W2529434198","https://openalex.org/W2531107174","https://openalex.org/W2537925564","https://openalex.org/W2552021548","https://openalex.org/W2567188480","https://openalex.org/W2576721970","https://openalex.org/W2590597646","https://openalex.org/W2593723184","https://openalex.org/W2594796758","https://openalex.org/W2596138695","https://openalex.org/W2596259431","https://openalex.org/W2599636694","https://openalex.org/W2603467063","https://openalex.org/W2604776612","https://openalex.org/W2606120108","https://openalex.org/W2607267898","https://openalex.org/W2611337374","https://openalex.org/W2612365855","https://openalex.org/W2614011808","https://openalex.org/W2620016413","https://openalex.org/W2622843898","https://openalex.org/W2626335421","https://openalex.org/W2727891259","https://openalex.org/W2731995447","https://openalex.org/W2750119425","https://openalex.org/W2751037830","https://openalex.org/W2756923622","https://openalex.org/W2765175017","https://openalex.org/W2766826981","https://openalex.org/W2772566228","https://openalex.org/W2775974766","https://openalex.org/W2782806265","https://openalex.org/W2783510107","https://openalex.org/W2784521119","https://openalex.org/W2805341297","https://openalex.org/W2891838475","https://openalex.org/W2893656056","https://openalex.org/W2904369958","https://openalex.org/W2913361626","https://openalex.org/W2913703682","https://openalex.org/W2921247651","https://openalex.org/W2971850845","https://openalex.org/W4255468921"],"related_works":["https://openalex.org/W3002644153","https://openalex.org/W3087086977","https://openalex.org/W3030367358","https://openalex.org/W2773382289","https://openalex.org/W2121757574","https://openalex.org/W2052840623","https://openalex.org/W2891781364","https://openalex.org/W2946079825","https://openalex.org/W2184857247","https://openalex.org/W2009426416"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Proteasome":[1,22],"inhibitors":[2],"(PIs)":[3],"are":[4],"therapeutic":[5],"backbones":[6],"of":[7,16,37,39,63,72,75,112,155,164,173,184],"multiple":[8,25,134],"myeloma":[9,30,67,135],"treatment,":[10],"with":[11,35,101,131,177],"PI-based":[12],"therapies":[13],"being":[14],"standards":[15],"care":[17],"throughout":[18],"the":[19,60,73,79,108,121,153,195],"treatment":[20,81,192],"algorithm.":[21,82],"inhibition":[23,65,77],"affects":[24],"critical":[26],"signaling":[27],"pathways":[28],"in":[29,46,66,120,133,162,194],"cells":[31],"and":[32,42,50,68,94,104,116,123,144,166,186],"interacts":[33],"synergistically":[34],"mechanisms":[36],"action":[38],"other":[40],"conventional":[41],"novel":[43],"agents,":[44],"resulting":[45],"substantial":[47],"anti-myeloma":[48],"activity":[49],"at":[51],"least":[52],"additive":[53],"effects.":[54],"Areas":[55],"covered:":[56],"This":[57],"review":[58],"summarizes":[59],"biologic":[61],"effects":[62],"proteasome":[64,76],"provides":[69],"an":[70],"overview":[71],"importance":[74],"to":[78,107,129,151,180],"current":[80],"It":[83],"reviews":[84],"key":[85,171],"clinical":[86],"data":[87],"on":[88],"three":[89],"PIs,":[90],"specifically":[91],"bortezomib,":[92],"carfilzomib,":[93],"ixazomib;":[95],"assesses":[96],"ongoing":[97,174],"phase":[98],"3":[99],"trials":[100],"these":[102,156],"agents;":[103],"looks":[105],"ahead":[106],"increasingly":[109,190],"broad":[110],"role":[111],"both":[113],"approved":[114],"PIs":[115,117,132,161],"under":[118],"investigation":[119],"frontline":[122],"relapsed":[124],"settings.":[125],"Expert":[126],"commentary:":[127],"Progress":[128],"date":[130],"has":[136],"been":[137],"impressive,":[138],"but":[139],"there":[140],"remain":[141],"unmet":[142],"needs":[143],"challenges,":[145],"as":[146,148],"well":[147],"increasing":[149],"opportunities":[150],"optimize":[152],"use":[154],"agents.":[157],"Understanding":[158],"discrepancies":[159],"between":[160],"terms":[163],"efficacy":[165],"safety":[167],"profile":[168],"is":[169],"a":[170],"goal":[172],"research,":[175],"along":[176],"proteomics-based":[178],"efforts":[179],"identify":[181],"potential":[182],"biomarkers":[183],"sensitivity":[185],"resistance,":[187],"thereby":[188],"enabling":[189],"personalized":[191],"approaches":[193],"future.":[196]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":12},{"year":2019,"cited_by_count":6}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2018-11-29T00:00:00"}